PE-22-28
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Most antidepressant research has concentrated on monoamine transporters – serotonin, norepinephrine, dopamine. PE-22-28 enters from a different direction entirely. It targets a two-pore-domain potassium channel, TREK-1, whose role in regulating neuronal excitability and mood has only recently attracted sustained attention. The mechanism is not about flooding a synapse. It is about adjusting the threshold at which a neuron speaks.
TREK-1 (KCNK2) is a two-pore-domain background potassium channel that hyperpolarises neurons in hippocampus, prefrontal cortex, and dorsal raphe, holding them below firing threshold. Elevated TREK-1 tone is associated with depressive phenotypes; knockout mice are resistant to stress-induced behavioral despair.
PE-22-28 is a seven-residue C-terminal fragment of spadin, the propeptide of sortilin, truncated to retain TREK-1 binding affinity while removing residues responsible for rapid peptidase degradation. Channel-blocking potency is comparable or superior to the parent peptide with meaningfully improved in vitro stability.
TREK-1 inhibition depolarises dorsal raphe serotonergic neurons, increasing their firing rate and raising synaptic serotonin availability through a mechanism that bypasses the transporter targeted by SSRIs. Onset in rodent behavioral assays is faster than that observed with conventional antidepressant treatment.
Dentate gyrus neurogenesis is suppressed in chronic stress models and partially restored by PE-22-28 administration, with increased BrdU-positive cell counts observed in the subgranular zone of treated mice. BDNF-TrkB signaling appears engaged downstream, though direct receptor interaction has not been demonstrated.
What we observe
Mood and brain effects seen so far
The following observations are drawn from murine behavioral pharmacology and in vitro electrophysiology studies. No human clinical data exist for PE-22-28 as of 2025. Patterns described here reflect what the research record reports, not what any individual should expect.
01
Antidepressant Effects
02
Rapid Onset
03
Hippocampal Neurogenesis
04
Serotonergic Modulation
05
Anxiogenic Signal
06
Intranasal Bioavailability
Evidence
What research says on PE-22-28
The evidence base for PE-22-28 consists of a small corpus of academic preclinical studies, largely from the originating laboratory in Valbonne and collaborating European groups. The work is methodologically careful within its scope. The gap between rodent behavioral pharmacology and human therapeutic application remains wide and unbridged.
PE-22-28, a truncated form of the antidepressant spadin, displays improved pharmacological and pharmacokinetic properties
Mazella and colleagues compared PE-22-28 directly against the full-length spadin peptide in TREK-1 channel inhibition assays and murine behavioral models. PE-22-28 demonstrated equivalent TREK-1 blocking potency with a fourfold improvement in resistance to peptidase degradation in plasma preparations. In forced-swim testing, PE-22-28 reduced immobility at a lower molar dose than spadin, and the effect was absent in TREK-1 knockout controls – confirming target specificity. The authors proposed PE-22-28 as the preferred analogue for further mechanistic investigation.
TREK-1 inhibition by PE-22-28 promotes hippocampal neurogenesis and serotonergic signaling in a chronic mild stress model
Using a 28-day chronic mild stress protocol in adult male mice, investigators administered PE-22-28 intranasally at 1 mg/kg daily and compared outcomes to fluoxetine (10 mg/kg oral) and vehicle controls. PE-22-28-treated animals showed significant reductions in sucrose preference deficit and coat-state deterioration. Dentate gyrus BrdU labeling revealed a 38% increase in proliferating cells versus vehicle. Hippocampal microdialysis confirmed elevated extracellular serotonin in PE-22-28 and fluoxetine groups, with PE-22-28 reaching significance at day 7 versus day 21 for fluoxetine.
Intranasal delivery of PE-22-28 achieves central antidepressant-like effects with a favorable acute tolerability profile in rodents
A tolerability-focused study examined acute and subacute intranasal PE-22-28 administration across a dose range of 0.1–10 mg/kg in rats. Behavioral antidepressant-like effects were observed from 0.5 mg/kg upward. No significant changes in locomotor activity, body temperature, or food intake were recorded at therapeutic doses. Elevated plus-maze performance was not adversely affected, and no seizure activity was observed on EEG monitoring. The authors noted the absence of anxiogenic signal as mechanistically consistent with TREK-1’s limited expression in amygdala circuits relative to hippocampus.
From lyophilized powder to a usable solution.
Peptide
10 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
3.33 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
- Protect from light.
- Use amber or opaque vials where possible; PE-22-28 contains a tyrosine residue susceptible to photo-oxidation under prolonged UV exposure
- Do not store near strong oxidizing agents; the methionine-free sequence reduces oxidation risk but does not eliminate it entirely
Side effects
What members describe
- No human adverse event data exist; all tolerability observations are from rodent studies and cannot be directly extrapolated
- In rodent studies, no significant changes in locomotor activity, body weight, or food intake were recorded at doses producing behavioral effects
- Theoretical concern: TREK-1 inhibition increases neuronal excitability; the potential for pro-convulsant effects at supratherapeutic doses has not been fully characterized across species
- Intranasal administration in rodents was not associated with local irritation markers in published studies; mucosal tolerability in humans is unknown
- Given the serotonergic downstream effects, theoretical interaction with serotonergic agents (SSRIs, MAOIs) warrants caution; no interaction studies have been conducted
Contradictions
Reasons to abstain
- No human contraindication data exist; the following are precautionary considerations based on mechanism
- Concurrent use with serotonergic medications is a theoretical concern given PE-22-28's downstream serotonin-elevating effects in rodent models
- Individuals with a personal or family history of seizure disorders should note the theoretical excitability-raising mechanism, pending further characterization
- Pregnancy and lactation: no safety data of any kind; use in these populations cannot be considered in any research context without specific ethical review
- Not appropriate for self-administration outside a supervised research protocol; the absence of human pharmacokinetic data makes independent use scientifically unjustifiable
Synergies
Good PE-22-28 combos
The following pairings reflect mechanistic logic drawn from the preclinical literature – not clinical protocols. They represent intellectual frameworks for understanding how PE-22-28 might complement other compounds under study. Aeterna does not prescribe combinations. No stacking protocol has been validated in human subjects.
FAQ
Your questions, patiently answered
Most approved antidepressants act by blocking the reuptake of monoamines – serotonin, norepinephrine, or both – at the synaptic cleft. PE-22-28 operates upstream of that, at the level of membrane excitability. By inhibiting TREK-1, a background potassium channel that holds neurons below firing threshold, it alters the conditions under which serotonergic neurons activate rather than the fate of serotonin once released. Whether this mechanistic distinction translates to a clinically meaningful difference in humans is not yet known.
The honest answer is that the literature does not fully explain the absence of clinical development. The compound originates from an academic laboratory rather than a pharmaceutical sponsor, which limits the resources available for IND-enabling studies. Additionally, the preclinical evidence base, while internally consistent, remains narrow – concentrated in a small number of research groups. Regulatory agencies require a substantially broader safety and pharmacokinetic dataset before human trials can begin.
No. Spadin is a 17-amino-acid peptide derived from the propeptide of sortilin. PE-22-28 is a seven-residue C-terminal fragment of spadin – specifically residues 22 through 28 of the propeptide sequence. The truncation was deliberate: researchers identified that the C-terminal region carried the TREK-1 pharmacophore while the N-terminal residues contributed primarily to peptidase susceptibility. PE-22-28 retains the channel-blocking activity with improved metabolic stability in vitro.
The blood-brain barrier presents a formidable obstacle to peptide delivery. Intranasal administration exploits the olfactory and trigeminal nerve pathways, which provide anatomical continuity between the nasal mucosa and the CNS, bypassing the need for systemic circulation to reach central targets. In rodent studies, intranasal PE-22-28 produced central behavioral effects consistent with brain penetration. Whether the same pathway operates with comparable efficiency in humans – whose olfactory anatomy differs meaningfully from rodents – is not established.
This is one of the more discussed observations in the PE-22-28 literature. In several murine behavioral studies, antidepressant-like effects were measurable within 24–48 hours of administration – a timeline that contrasts sharply with the 2–4 week clinical latency of SSRIs. The proposed explanation is mechanistic: TREK-1 inhibition produces an immediate electrophysiological shift in neuronal excitability, whereas SSRI efficacy depends on gradual receptor desensitization and downstream neuroplastic changes that accumulate over weeks. Whether this rapid onset would translate to human subjects is entirely speculative at present.
As of 2025, PE-22-28 remains a preclinical research compound with no registered clinical trials. The published literature is largely the product of the originating CNRS laboratory and a small number of European collaborators. Interest in TREK-1 as a therapeutic target has grown modestly alongside broader attention to two-pore-domain potassium channels in neuropsychiatric pharmacology. Whether a pharmaceutical sponsor will adopt PE-22-28 or a structural analogue for clinical development is not predictable from the current record. The compound’s value at present is primarily as a tool for understanding TREK-1 biology.
In the same family
Further reading in the curriculum
Sourcing · Independently verified
When you're ready, source thoughtfully.